Approval · Notice of Compliance 28330 · 2022
ZEJULA: Notice of Compliance 28330
Issued June 6, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28330
- Date
- June 6, 2022
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZEJULA | Not yet assigned | — |
Medicinal ingredients
- NIRAPARIB 100 MG per CAP